ES2400450T3 - Derivados de pirazolo[1,5-a][1,3,5]triazina y pirazolo[1,5-a]pirimidina para uso como inhibidores de la proteina quinasa - Google Patents

Derivados de pirazolo[1,5-a][1,3,5]triazina y pirazolo[1,5-a]pirimidina para uso como inhibidores de la proteina quinasa Download PDF

Info

Publication number
ES2400450T3
ES2400450T3 ES07838443T ES07838443T ES2400450T3 ES 2400450 T3 ES2400450 T3 ES 2400450T3 ES 07838443 T ES07838443 T ES 07838443T ES 07838443 T ES07838443 T ES 07838443T ES 2400450 T3 ES2400450 T3 ES 2400450T3
Authority
ES
Spain
Prior art keywords
amino
phenyl
pyrazolo
triazin
diaza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07838443T
Other languages
English (en)
Spanish (es)
Inventor
Shaosong Chu
Zhe Nie
Carin L. Perretta
Philip Eugene Erickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polaris Group Taiwan
Original Assignee
Polaris Group Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polaris Group Taiwan filed Critical Polaris Group Taiwan
Application granted granted Critical
Publication of ES2400450T3 publication Critical patent/ES2400450T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES07838443T 2006-09-18 2007-09-18 Derivados de pirazolo[1,5-a][1,3,5]triazina y pirazolo[1,5-a]pirimidina para uso como inhibidores de la proteina quinasa Active ES2400450T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84531406P 2006-09-18 2006-09-18
US845314P 2006-09-18
US11/856,476 US7517882B2 (en) 2006-09-18 2007-09-17 Protein kinase inhibitors
US856476 2007-09-17
PCT/US2007/020231 WO2008036277A1 (en) 2006-09-18 2007-09-18 Pyraz0l0(l,5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2400450T3 true ES2400450T3 (es) 2013-04-10

Family

ID=39052753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07838443T Active ES2400450T3 (es) 2006-09-18 2007-09-18 Derivados de pirazolo[1,5-a][1,3,5]triazina y pirazolo[1,5-a]pirimidina para uso como inhibidores de la proteina quinasa

Country Status (11)

Country Link
US (2) US7517882B2 (enExample)
EP (1) EP2064214B1 (enExample)
JP (1) JP5232786B2 (enExample)
KR (1) KR101418619B1 (enExample)
CN (1) CN101522683B (enExample)
AU (1) AU2007297675B2 (enExample)
BR (1) BRPI0718459A2 (enExample)
CA (1) CA2663791C (enExample)
ES (1) ES2400450T3 (enExample)
TW (1) TWI472530B (enExample)
WO (1) WO2008036277A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
AU2009233963B2 (en) * 2008-04-07 2011-10-06 Irm Llc Compounds and compositions as kinase inhibitors
KR20140078710A (ko) * 2011-09-30 2014-06-25 온코디자인 에스.에이. 거대고리 flt3 키나제 억제제
CN105209040A (zh) * 2013-03-15 2015-12-30 昂科迪塞恩股份有限公司 大环的盐可诱导的激酶抑制剂
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
JP6789962B2 (ja) * 2015-03-09 2020-11-25 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体
RU2019105587A (ru) * 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
JP7586829B2 (ja) * 2019-03-11 2024-11-19 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
SG11202110523XA (en) * 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10255343B4 (de) * 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US7482354B2 (en) * 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MXPA06013996A (es) * 2004-06-02 2007-02-08 Takeda Pharmaceutical Compuesto heterociclico fusionado.
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors

Also Published As

Publication number Publication date
KR101418619B1 (ko) 2014-07-14
JP2010503690A (ja) 2010-02-04
TWI472530B (zh) 2015-02-11
CN101522683B (zh) 2013-02-27
US20080070893A1 (en) 2008-03-20
KR20090083889A (ko) 2009-08-04
WO2008036277A1 (en) 2008-03-27
US7517882B2 (en) 2009-04-14
AU2007297675A1 (en) 2008-03-27
CA2663791A1 (en) 2008-03-27
EP2064214A1 (en) 2009-06-03
TW200837065A (en) 2008-09-16
BRPI0718459A2 (pt) 2013-12-03
EP2064214B1 (en) 2013-01-30
AU2007297675B2 (en) 2012-09-20
CA2663791C (en) 2015-11-03
CN101522683A (zh) 2009-09-02
JP5232786B2 (ja) 2013-07-10
US20090247501A1 (en) 2009-10-01
HK1135688A1 (en) 2010-06-11

Similar Documents

Publication Publication Date Title
ES2400450T3 (es) Derivados de pirazolo[1,5-a][1,3,5]triazina y pirazolo[1,5-a]pirimidina para uso como inhibidores de la proteina quinasa
AU2007316417B2 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US8431596B2 (en) [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
JP7094438B2 (ja) 大環状キナーゼ阻害剤
CN113527299B (zh) 一类含氮稠环类化合物、制备方法和用途
AU2005267120A1 (en) Imidazopyrazine as tyrosine kinase inhibitors
ES2540962T3 (es) Derivados de azaindoles como inhibidores de las proteína cinasas Abl y Src
Shao et al. Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl) benzamides as novel PI3K inhibitors and anticancer agents by bioisostere
CN109721600B (zh) 一类含氮稠环化合物及其制备方法和用途
CN116675653B (zh) 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
WO2011036461A1 (en) Fused imidazo [3, 2 - d] pyrazines as pi3 kinase inhibitors
CN117645598A (zh) 氮杂二并多元稠环化合物及其药物组合物和应用
CN114685520B (zh) 三并环化合物及其药物组合物和应用
JP5260627B2 (ja) ベンゾフェノン化合物及びその作製方法
PL236355B1 (pl) Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CN114026089B (zh) 取代的萘二酰亚胺及其用途
CN117143107A (zh) 1,2-二氢吡啶类衍生物及其制备方法和用途
HK1135688B (en) Pyrazolo (1,5-a)(1,3,5) triazine and pyrazolo (1,5-a) pyrimidine derivatives useful as protein kinase inhibitors
BRPI0619955A2 (pt) derivados tricìclicos da lactama, sua produção e seus usos como agentes farmacêuticos
WO2021038419A1 (en) Kinase inhibitors and methods of synthesis and treatment
HK1233639A1 (en) Isoquinolinone derivatives useful in the treatment of cancer